Search
Harmony Biosciences Holdings Inc
HRMYAdd to Watchlist
33.280USD
-0.490-1.45%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
1.93BMarket Cap
13.17P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Harmony Biosciences Holdings Inc is 7.09, ranking 111 out of 157 in the Pharmaceuticals industry. The average price target is 47.00, with a high of 62.00 and a low of 32.00.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
44.364
Target Price
+33.30%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Harmony Biosciences Holdings Inc
HRMY
11
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Harmony Biosciences Holdings Inc's expected revenue for the next quarter?
Harmony Biosciences Holdings Inc's expected revenue is 242.06M.
What is Harmony Biosciences Holdings Inc's price target?
Analysts forecast that Harmony Biosciences Holdings Inc's price target is USD 47.00, with the highest forecast at USD 62.00 and the lowest forecast at USD 32.00.
How have Harmony Biosciences Holdings IncHRMY's recent earnings per share performed?
The market expectation was USD 0.56, while Harmony Biosciences Holdings IncHRMY's earnings per share (EPS) for the previous quarter was USD 0.39. EPS for the next quarter is expected at USD 0.93.
What is the analyst rating for Harmony Biosciences Holdings Inc?
Based on the ratings of Harmony Biosciences Holdings Inc's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
